Celldex Therapeutics, Inc. (CLDX)
Nasdaq · Healthcare · Biotechnology
$32.59+2.97%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $2.6B
- 52-week range
- $22.10 – $45.14
- 52-week change
- +20.71%
- EPS (trailing)
- −$4.35
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $1.5M (−77.99%)
- Net income
- −$259M
- Operating margin
- −18600.0%
- Diluted EPS
- −$3.90
- Free cash flow
- −$214M
From the company’s annual report on SEC EDGAR.
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Headquarters: Hampton, United States · 198 employees · celldex.com